Woods D - Search Results

1

A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.

Mitra A, Thompson B, Strange A, Amato CM, Vassallo M, Dolgalev I, Hester-McCullough J, Muramatsu T, Kimono D, Puranik AS, Weber JS, Woods D. Mitra A, et al. Among authors: woods d. Clin Cancer Res. 2023 Oct 13;29(20):4242-4255. doi: 10.1158/1078-0432.CCR-23-0653. Clin Cancer Res. 2023. PMID: 37505479 Free PMC article.

2

CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy.

Thompson B, Strange A, Amato CM, Hester-McCullough J, Sarnaik AA, Weber JS, Woods DM. Thompson B, et al. J Immunol. 2023 Sep 1;211(5):735-742. doi: 10.4049/jimmunol.2300250. J Immunol. 2023. PMID: 37466381

3

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.

Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS. Woods DM, et al. Clin Cancer Res. 2018 Dec 15;24(24):6236-6247. doi: 10.1158/1078-0432.CCR-18-1100. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131384 Free PMC article.

4

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.

Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Ichikawa J, et al. Among authors: woods d. Clin Cancer Res. 2020 Jul 1;26(13):3384-3396. doi: 10.1158/1078-0432.CCR-19-3487. Epub 2020 Apr 2. Clin Cancer Res. 2020. PMID: 32241816 Free PMC article.

5

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.

Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J. Laino AS, et al. Among authors: woods d. J Immunother Cancer. 2020 Jun;8(1):e000842. doi: 10.1136/jitc-2020-000842. Epub 2020 Jun 23. J Immunother Cancer. 2020. PMID: 32581042 Free PMC article.

6

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.

Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. Among authors: woods dm. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.

7

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM. Laino AS, et al. J Immunother Cancer. 2019 Feb 6;7(1):33. doi: 10.1186/s40425-019-0517-0. J Immunother Cancer. 2019. PMID: 30728070 Free PMC article.

8

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.

Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F, Weber J. Yoshida T, et al. J Immunother Cancer. 2020 Apr;8(1):e000234. doi: 10.1136/jitc-2019-000234. J Immunother Cancer. 2020. PMID: 32303612 Free PMC article.

9

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.

Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Weber JS, et al. Melanoma Res. 2022 Oct 1;32(5):324-333. doi: 10.1097/CMR.0000000000000818. Epub 2022 Jun 9. Melanoma Res. 2022. PMID: 35678233 Free PMC article. Clinical Trial.

10

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG. Briere D, et al. Among authors: woods dm. Cancer Immunol Immunother. 2018 Mar;67(3):381-392. doi: 10.1007/s00262-017-2091-y. Epub 2017 Nov 9. Cancer Immunol Immunother. 2018. PMID: 29124315 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,990 results

Search Page